Capricor now partners with Nippon Shinyaku for CAP-1002 in Japan

16 February 2023

US biotech Capricor Therapeutics (Nasdaq: CAPR) has entered into a partnership with mid-sized Japanese drugmaker Nippon Shinyaku (TYO: 4516), for the exclusive commercialization and distribution in Japan of Capricor’s lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD), a rare neuromuscular disease with limited treatment options.

Capricor’s shares gained 12.8% to $4.54 on the development, which follows the exclusive commercialization and distribution agreement entered into with Nippon Shinyaku in the USA in January 2022.

This new deal allows Capricor to expand its partnership with Nippon Shinyaku to Japan to leverage its deep expertise in drug development for rare diseases and commercial DMD franchise.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK